IceCure Medical Secures U.S. Patent Allowance for Cryogen Flow Control

An update from Icecure Medical ( (ICCM) ) is now available.

On June 9, 2025, IceCure Medical announced it received a Notice of Allowance from the United States Patent and Trademark Office for its ‘Cryogen Flow Control’ patent application. This patent, once granted, will be valid until 2045 and is expected to enhance the efficiency of cryoablation procedures by optimizing cryogen delivery. The announcement highlights IceCure’s strategic expansion of its intellectual property assets as it awaits FDA marketing approval for its ProSense® system in early-stage breast cancer treatment. This development is anticipated to strengthen IceCure’s position as a leader in liquid nitrogen-based cryoablation technology, potentially increasing its market traction.

The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

IceCure Medical’s overall stock score is primarily impacted by its financial performance challenges, including ongoing losses and cash flow issues. While technical indicators and valuation remain weak, there is potential upside from positive regulatory and sales developments highlighted in the earnings call. However, the risks associated with financial instability are significant.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, is a developer and marketer of advanced cryoablation therapy systems that utilize liquid nitrogen to destroy tumors by freezing. The company’s primary focus areas include breast, kidney, bone, and lung cancer. IceCure’s minimally invasive technology offers a safe alternative to surgical tumor removal, with its flagship ProSense® system marketed globally for approved indications.

Average Trading Volume: 261,138

Technical Sentiment Signal: Sell

Current Market Cap: $57.42M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.